Immunoassay Evaluated For Tularemia Diagnosis
By LabMedica International staff writers Posted on 12 Sep 2012 |
The laboratory diagnosis of tularemia is usually based on direct detection of the bacteria either by culture or by nucleic acid amplification techniques and on detection of elevated antibody titers.
A simple, rapid, and affordable point-of-care immunochromatographic assay has been evaluated that may assist in narrowing the differential diagnosis and would be useful for early diagnosis and treatment and for public health surveillance.
Scientists at Public Health Institution (Ankara, Turkey) tested a panel of 221 sera from 109 cases of tularemia as well as 236 sera from normal individuals or individuals with other infectious or autoimmune diseases. A commercially available immunochromatographic assay (ICA) for the serologic diagnosis of tularemia was evaluated, and the performance was compared with that of the current standard, the microagglutination test (MAT).
The VIRapid Tularemia ICA (Vircell; Granada, Spain) was manufactured using lipopolysaccharides (LPS) extracted by the hot phenol–water method from Francisella tularensis cell suspension. LPS was adsorbed on both the conjugate and the test line to generate a lateral flow ICA. A control line was also included to check the correct performance of the test. The test was performed by the addition of serum to the sample pad of the assay device followed by the addition of running fluid. Test results were read after 15 minutes by visual inspection for staining of the antigen and control lines. The intensity of staining of the reaction band was read visually and scored from one to three with a color reference diagram.
The ICA demonstrated 91.5% agreement with the MAT reference method and gave an overall sensitivity of 99.3% and a specificity of 94.6%. When only acute-phase sera were considered, the sensitivity and specificity of the ICA were 100% and 95.5%, respectively. No cross-reactivity was observed in the ICA with serum samples from normal individuals and patients with autoimmune diseases and bacterial, viral, and parasitic infections, although 4 out of 50 patients with brucellosis demonstrated positive results in the ICA.
The authors concluded that ICA showed higher positivity with early acute-phase sera than the reference MAT, while retaining high specificity. The assay should greatly improve the rapid detection of tularemia in the field and facilitate the rapid determination of the extent of public health threat especially in outbreak situations. Tularemia is an infection caused by F. tularensis, a Gram-negative, nonmotile coccobacillus, with a worldwide distribution in the northern hemisphere and diverse clinical manifestations. Humans become infected through arthropod bites, handling of infected animal tissues, or ingestion of contaminated water or food, and inhalation of infectious aerosols. The study was published in the September 2012 issue of the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Public Health Institution of Turkey
Vircell
A simple, rapid, and affordable point-of-care immunochromatographic assay has been evaluated that may assist in narrowing the differential diagnosis and would be useful for early diagnosis and treatment and for public health surveillance.
Scientists at Public Health Institution (Ankara, Turkey) tested a panel of 221 sera from 109 cases of tularemia as well as 236 sera from normal individuals or individuals with other infectious or autoimmune diseases. A commercially available immunochromatographic assay (ICA) for the serologic diagnosis of tularemia was evaluated, and the performance was compared with that of the current standard, the microagglutination test (MAT).
The VIRapid Tularemia ICA (Vircell; Granada, Spain) was manufactured using lipopolysaccharides (LPS) extracted by the hot phenol–water method from Francisella tularensis cell suspension. LPS was adsorbed on both the conjugate and the test line to generate a lateral flow ICA. A control line was also included to check the correct performance of the test. The test was performed by the addition of serum to the sample pad of the assay device followed by the addition of running fluid. Test results were read after 15 minutes by visual inspection for staining of the antigen and control lines. The intensity of staining of the reaction band was read visually and scored from one to three with a color reference diagram.
The ICA demonstrated 91.5% agreement with the MAT reference method and gave an overall sensitivity of 99.3% and a specificity of 94.6%. When only acute-phase sera were considered, the sensitivity and specificity of the ICA were 100% and 95.5%, respectively. No cross-reactivity was observed in the ICA with serum samples from normal individuals and patients with autoimmune diseases and bacterial, viral, and parasitic infections, although 4 out of 50 patients with brucellosis demonstrated positive results in the ICA.
The authors concluded that ICA showed higher positivity with early acute-phase sera than the reference MAT, while retaining high specificity. The assay should greatly improve the rapid detection of tularemia in the field and facilitate the rapid determination of the extent of public health threat especially in outbreak situations. Tularemia is an infection caused by F. tularensis, a Gram-negative, nonmotile coccobacillus, with a worldwide distribution in the northern hemisphere and diverse clinical manifestations. Humans become infected through arthropod bites, handling of infected animal tissues, or ingestion of contaminated water or food, and inhalation of infectious aerosols. The study was published in the September 2012 issue of the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Public Health Institution of Turkey
Vircell
Latest Microbiology News
- Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more